EXACT Sciences Net Income
| EXAS Stock | USD 102.51 0.01 0.01% |
As of the 3rd of February, EXACT Sciences owns the Market Risk Adjusted Performance of (2.84), standard deviation of 3.76, and Coefficient Of Variation of 539.39. EXACT Sciences technical analysis allows you to utilize past data patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm EXACT Sciences standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if EXACT Sciences is priced correctly, providing market reflects its prevailing price of 102.51 per share. Given that EXACT Sciences has treynor ratio of (2.85), we urge you to verify EXACT Sciences's latest market performance to make sure the company can sustain itself in the future.
EXACT Sciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing EXACT Sciences' valuation are provided below:EXACT Sciences does not today have any fundamental measures for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is there potential for Stock market expansion? Will EXACT introduce new products? Factors like these will boost the valuation of EXACT Sciences. Projected growth potential of EXACT fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about EXACT Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of EXACT Sciences is measured differently than its book value, which is the value of EXACT that is recorded on the company's balance sheet. Investors also form their own opinion of EXACT Sciences' value that differs from its market value or its book value, called intrinsic value, which is EXACT Sciences' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because EXACT Sciences' market value can be influenced by many factors that don't directly affect EXACT Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between EXACT Sciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding EXACT Sciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, EXACT Sciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
EXACT Sciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to EXACT Sciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of EXACT Sciences.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in EXACT Sciences on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding EXACT Sciences or generate 0.0% return on investment in EXACT Sciences over 90 days. EXACT Sciences is related to or competes with Guardant Health, ICON PLC, Viatris, BridgeBio Pharma, Summit Therapeutics, Revvity, and Roivant Sciences. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and international... More
EXACT Sciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure EXACT Sciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess EXACT Sciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 0.8919 | |||
| Information Ratio | 0.1713 | |||
| Maximum Drawdown | 24.01 | |||
| Value At Risk | (0.91) | |||
| Potential Upside | 1.38 |
EXACT Sciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for EXACT Sciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as EXACT Sciences' standard deviation. In reality, there are many statistical measures that can use EXACT Sciences historical prices to predict the future EXACT Sciences' volatility.| Risk Adjusted Performance | 0.1441 | |||
| Jensen Alpha | 0.698 | |||
| Total Risk Alpha | 0.4672 | |||
| Sortino Ratio | 0.7227 | |||
| Treynor Ratio | (2.85) |
EXACT Sciences February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1441 | |||
| Market Risk Adjusted Performance | (2.84) | |||
| Mean Deviation | 1.42 | |||
| Downside Deviation | 0.8919 | |||
| Coefficient Of Variation | 539.39 | |||
| Standard Deviation | 3.76 | |||
| Variance | 14.16 | |||
| Information Ratio | 0.1713 | |||
| Jensen Alpha | 0.698 | |||
| Total Risk Alpha | 0.4672 | |||
| Sortino Ratio | 0.7227 | |||
| Treynor Ratio | (2.85) | |||
| Maximum Drawdown | 24.01 | |||
| Value At Risk | (0.91) | |||
| Potential Upside | 1.38 | |||
| Downside Variance | 0.7955 | |||
| Semi Variance | (0.38) | |||
| Expected Short fall | (1.48) | |||
| Skewness | 5.25 | |||
| Kurtosis | 28.71 |
EXACT Sciences Backtested Returns
EXACT Sciences appears to be very steady, given 3 months investment horizon. EXACT Sciences retains Efficiency (Sharpe Ratio) of 0.19, which denotes the company had a 0.19 % return per unit of risk over the last 3 months. By analyzing EXACT Sciences' technical indicators, you can evaluate if the expected return of 0.7% is justified by implied risk. Please utilize EXACT Sciences' Coefficient Of Variation of 539.39, market risk adjusted performance of (2.84), and Standard Deviation of 3.76 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, EXACT Sciences holds a performance score of 14. The firm owns a Beta (Systematic Risk) of -0.24, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning EXACT Sciences are expected to decrease at a much lower rate. During the bear market, EXACT Sciences is likely to outperform the market. Please check EXACT Sciences' standard deviation, expected short fall, relative strength index, as well as the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether EXACT Sciences' current price history will revert.
Auto-correlation | 0.87 |
Very good predictability
EXACT Sciences has very good predictability. Overlapping area represents the amount of predictability between EXACT Sciences time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of EXACT Sciences price movement. The serial correlation of 0.87 indicates that approximately 87.0% of current EXACT Sciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.87 | |
| Spearman Rank Test | 0.8 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, EXACT Sciences reported net income of (1.03 Billion). This is 401.47% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is significantly higher than that of the company.
EXACT Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EXACT Sciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of EXACT Sciences could also be used in its relative valuation, which is a method of valuing EXACT Sciences by comparing valuation metrics of similar companies.EXACT Sciences is currently under evaluation in net income category among its peers.
EXACT Fundamentals
| Return On Equity | -0.35 | |||
| Return On Asset | -0.0109 | |||
| Profit Margin | (0.32) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 20.95 B | |||
| Shares Outstanding | 189.92 M | |||
| Shares Owned By Insiders | 1.20 % | |||
| Shares Owned By Institutions | 93.44 % | |||
| Number Of Shares Shorted | 7.54 M | |||
| Price To Earning | (38.17) X | |||
| Price To Book | 7.77 X | |||
| Price To Sales | 6.32 X | |||
| Revenue | 2.76 B | |||
| Gross Profit | 2.14 B | |||
| EBITDA | (789.33 M) | |||
| Net Income | (1.03 B) | |||
| Cash And Equivalents | 728.04 M | |||
| Cash Per Share | 4.11 X | |||
| Total Debt | 2.75 B | |||
| Debt To Equity | 0.77 % | |||
| Current Ratio | 2.48 X | |||
| Book Value Per Share | 13.20 X | |||
| Cash Flow From Operations | 210.54 M | |||
| Short Ratio | 2.81 X | |||
| Earnings Per Share | (5.35) X | |||
| Price To Earnings To Growth | (1.07) X | |||
| Target Price | 105.81 | |||
| Number Of Employees | 6.9 K | |||
| Beta | 1.42 | |||
| Market Capitalization | 19.47 B | |||
| Total Asset | 5.93 B | |||
| Retained Earnings | (4.5 B) | |||
| Working Capital | 839.24 M | |||
| Current Asset | 325.86 M | |||
| Current Liabilities | 26.72 M | |||
| Net Asset | 5.93 B |
About EXACT Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EXACT Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EXACT Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EXACT Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for EXACT Stock Analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.